Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBITDA (2020 - 2023)

Historic EBITDA for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.1 million.

  • Immuneering's EBITDA fell 1489.86% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.4 million, marking a year-over-year decrease of 583.74%. This contributed to the annual value of -$53.4 million for FY2023, which is 583.74% down from last year.
  • Immuneering's EBITDA amounted to -$15.1 million in Q4 2023, which was down 1489.86% from -$12.6 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's EBITDA ranged from a high of -$3.6 million in Q2 2020 and a low of -$15.1 million during Q4 2023
  • For the 4-year period, Immuneering's EBITDA averaged around -$10.1 million, with its median value being -$11.5 million (2022).
  • In the last 5 years, Immuneering's EBITDA crashed by 12147.17% in 2021 and then soared by 170.13% in 2023.
  • Quarter analysis of 4 years shows Immuneering's EBITDA stood at -$5.8 million in 2020, then plummeted by 85.55% to -$10.8 million in 2021, then fell by 21.28% to -$13.1 million in 2022, then decreased by 14.9% to -$15.1 million in 2023.
  • Its EBITDA stands at -$15.1 million for Q4 2023, versus -$12.6 million for Q3 2023 and -$12.2 million for Q2 2023.